EMAIL

genealign@genealign.com

Call Now

(214) 444-9555

Clinicians Pharmacogenetic Testing | Genetic Lab

  • Home
  • Clinicians Pharmacogenetic Testing | Genetic Lab

Pharmacogenetic Testing In Your Practice

Clinicians pharmacogenetic testing lab in your practice as personalized medicine becomes an integral part of medical practice, clinicians need access to actionable genetic data in order to individually treat their patients. With our customizable, low-risk solutions to pharmacogenetic testing, we seek to bring this service to the forefront of patient care.

Clinicians Pharmacogenetic Testing Process:

  • Patient sample is taken with a single cheek swab
  • Pharmacogenetic Testing is driven by medical necessity
  • DNA analysis is performed in our lab or in your own facility
  • Results are delivered in static paper form or through our interactive software solution
  • Decision support is based on drug to gene and drug to drug interactions

Clinicians Pharmacogenetic Testing Results:

  • Doctor-friendly reporting facilitates clinical decision-making
  • Reduce your patients’ risks of adverse drug events
  • Increase therapeutic benefit of medication intervention
  • New service offering for your practice

Multiple Testing Panels

Lab Testing Services, PGx Genetic Testing, lab testing services, toxicology and pharmacogenomics pharmacogenetic testing

Cardiovascular Panel

  • Ensure that your patients are getting the treatment they need for better heart health, reducing the likelihood of a life-threatening cardiovascular event
  • Drug classes on the CV panel include: antiarrhythmics, anticoagulants, antidiabetics, antihypertensives, platelet aggregation inhibitors, statins, and thrombophilias

Pain Panel

  • Assists in the targeted selection of medication used to treat patients with acute and chronic pain
  • PGx data on three classes of pain medications: NSAIDS, opioids, and opioid antagonists

Psychiatric Panel

  • Used in the treatment of patients suffering from anxiety, depression, bipolar disorder and other behavioral disorders
  • Available testing for antidepressants, antipsychotics, benzodiazepines, norepinephrine reuptake inhibitors, substituted amphetamines and more

Pain + Psych Panel

  • Assists clinicians in the targeted selection of medication used to treat patients with acute and chronic pain
  • Patients can receive the right medications they need in the optimal doses, providing faster and more efficient symptom relief.

Comprehensive Panel

  • We combined our three individual panels (Pain, Psych and Cardio) to form a "Personalize Medicine Panel".
  • In combination with patient-reported adherence questionnaires, physicians can ensure that their patients are getting the treatment they need for better heart health, reducing the likelihood of a life-threatening cardiovascular event.

Future Panels

  • As part of this growing industry, GeneAlign is committed to providing the latest PGx offerings to address the various needs of our customers, improving patient care every step of way.

CLINICAL PHARMACOGENETIC TESTING INFORMATION

Pharmacogenetics Testing focuses on the analysis of the genes responsible for the metabolism of medications and determines inherited variations that can affect your patients’ responses to certain medications.

  • It is estimated that 82% of adults in the U.S. take at least 1 drug and 29% take 5 or more1
  • 1 in every 2 patients has a gene variant that alters the metabolic rate of CYP450 enzymes
  • 10% of prescription drugs now have FDA labeling related to pharmacogenetics2

In addition, Adverse Drug Events annually account for:

  • 2 Million Serious Event3
  • 100,000 Deaths (4th leading cause of death in US)4
  • 700,000 emergency department visits and 120,000 hospital visits1
  • $3.5 billion spent on extra medical costs 1

BARRIERS TO PGX TESTING ADOPTION AMONG CLINICIANS

  1. The limited knowledge of the science of pharmacogenetics among physicians makes the results of the tests difficult to translate into clinical decisions.
  2. As an emerging field of scientific discovery impacting the practice of medicine, widespread adoption of pharmacogenetics has been slow, pending further evidence supporting its efficacy.
  3. The complexity of PGx test results in addition to confusing static paper reports creates a negative predisposition among clinicians to the usefulness of pharmacogenetics.
  4. Adoption of testing has been slow due to reimbursement inconsistencies among payers.
  5. Physicians are unsure which patients to test.

GeneAlign seeks to break-down the barriers hindering pharmacogenetics from clinical practice by providing a customized, low-risk, turnkey solution to PGx testing in combination with medical necessity documentation and intuitive decision support tools.

Frequently Asked Questions for Clinicians

How will this test help treat my patients?

  • Have a greater ability to predict patient’s response to medications
  • Variants usually result in a significant loss of function for the enzymes. This could result in the drug having a decreased or complete lack of efficacy, or worse, increased exposure to a medication can potentially lead to toxicity
  • Patients with gene variants are 8 times more likely to experience drug toxicity or lack of efficacy to their prescribed medications

Why should I implement PGx testing in my practice?

  • Improve and revolutionize patient care and safety through PGx testing
  • Have actionable genetic data at the point of care with easy to use decision support
  • New tools to follow medical necessity protocols and track outcomes
  • Incorporating personalized medicine techniques is a marketing advantage
  • Provides an additional service offering for comprehensive patient care

Provider Resources

Buccal Swab Collections Kit Instructions

Click Here to View/Dowload Swab Instructions

References

1 – https://www.cdc.gov/medicationsafety/basics.html

2 – https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm114848.htm

3 – U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion.
(2014). National Action Plan for Adverse Drug Event Prevention. Washington, DC: Author.

4 – New England Journal of Medicine, July 22, 2010